Wuhan Demeikai Biotechnology Co., Ltd
返回首页 | 加入收藏 | 设为首页
质量是服务的宗旨,24小时客服热线:13260607296
联系方式
Wuhan Demeikai Biotechnology Co., Ltd
whatsapp:+86 18942921723(Ms.Gao) 
+86 13260607296(Mr.Wang)
E-MAIL:wzh@dmksw.xin
Website:http://www.whdksj.com
Buy 99%+Regorafenib hydrate powder Home您现在的位置:HOME >> PRODUCTS >> Inhibitors

Buy 99%+Regorafenib hydrate powder

所属类别:Inhibitors 点击次数:881次 发布时间:2017-04-13

Regorafenib hydrate powder
详情
 
 
Product name:Regorafenib hydrate
Other names:BAY 73-4506 monohydrate
CAS No.:1019206-88-2
Molecular formula:C21H17ClF4N4O4
Molecular weight:500.83
Storage :Store at -20°C
Solubility:Soluble in DMSO
Product Specifications:Pharmacopoeial grade
Description 
Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
 
Regorafenib Application:
Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. 
Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. 
 
Regorafenib monohydrate is a multitargetedinhibitor of tyrosine kinase with IC50 values of 13nM, 4.2nM, 46nM, 2.5nM, 28nM, 19nM, 202nM, 22nM, 7nM, 1.5nM and 311nM, respectively for VEGFR-1, mVEGFR-2, mVEGFR-3, Raf-1, BRAF WT, BRAFV600E, FGFR-1, PDGFR-β, c-KIT, RETand TIE2.
Regorafenib is a multikinase inhibitor of both intracellular and membrane-bound RTKs. It shows potent inhibition of angiogenic and stromal RTKs like VEGF receptors-1-3, PDGFR-β and FGF receptor-1 with IC50 values ranging from4.2 to 311nM in biochemical assays. It also inhibits oncogenic RTKs, such as RET and c-KIT, with IC50 values ranging from 1.5 to 28nM in cellular assays.
 
Regrafenib is reported to have anti-tumor efficacy to various tumors including breast, pancreas, thyroid, melanoma, GIST, and CRC with a mean IC50 value less than 1μM. These inhibition effects of tumor growth are also found in mouse xenograft models after the treatment of regorafenib at dose ranging from 10 to 100 mg/kg.
 

上一产品: Buy Regorafenib powder
下一产品: Buy 99% + Imatinib Powder
友情链接:made-in-china | 西地那非原料药 | 伐地那非原料药 | 他达那非原料药 | 
Copyright © 2004-2015 Wuhan Demechem Bio-tech Co., Ltd All Rights Release all
whatsapp:8618942921723 Company address: wuchang district in wuhan city, hubei province austral soho north 4 1 unit。
收缩
  • QQ咨询

  • SKYPE
  • SKYPE
  • 电话咨询

  • 13260607296